Background
Methods
Patients
Clinical data collection
Patient follow-up
Statistical analysis
Results
Patient and tumor characteristics
Characteristics | Cases | Percentage (%) |
---|---|---|
Sex | 310 | |
Male | 174 | 56.1 |
Female | 136 | 43.9 |
Age at operation (years) | ||
< 50 | 208 | 67.1 |
≥ 50 | 102 | 32.9 |
Performance status | ||
0 | 237 | 76.5 |
≥ 1 | 73 | 23.5 |
Body mass index (kg/m2) | ||
< 18.5 | 42 | 13.5 |
≥ 18.5 to< 25.0 | 208 | 67.1 |
≥ 25.0 | 60 | 19.4 |
Pathological types | ||
Fibrosarcoma | 59 | 19.0 |
liposarcoma | 37 | 11.9 |
Undifferentiated pleomorphic sarcoma/MFH | 78 | 25.2 |
Leiomyosarcoma | 17 | 5.5 |
Synovial sarcoma | 40 | 12.9 |
Rhabdomyosarcoma | 19 | 6.1 |
Alveolar soft part sarcoma | 9 | 2.9 |
Angiosarcoma | 8 | 2.6 |
Malignant peripheral nerve sheath tumor | 15 | 4.8 |
Mesenchymal chondrosarcoma | 8 | 2.6 |
Others | 20 | 6.5 |
Tumor size (cm) | ||
< 5 | 143 | 46.1 |
≥ 5 | 167 | 53.9 |
Tumor site | ||
Upper extremity | 35 | 11.3 |
Lower extremity | 82 | 26.5 |
Thoracic/trunk/abdominal wall | 91 | 29.4 |
Intra-abdominal | 48 | 15.5 |
Head/neck | 48 | 15.5 |
Others | 6 | 1.9 |
Tumor depth | ||
Superficial | 127 | 41.0 |
Deep | 183 | 59.0 |
Tumor grade | ||
G1 | 82 | 26.5 |
G2 | 119 | 38.4 |
G3 | 80 | 25.8 |
Missing | 29 | 9.4 |
Surgical margin | ||
R0 | 279 | 95.2 |
R1 | 9 | 3.1 |
R2 | 3 | 1.0 |
Rx | 2 | 0.7 |
AJCC stage | ||
IA + IB | 83 | 26.8 |
IIA + IIB | 141 | 45.5 |
III + IV | 62 | 20.0 |
Missing | 24 | 7.1 |
NLR | ||
< 2.51 | 214 | 69.0 |
≥ 2.51 | 96 | 31.0 |
PLR | ||
< 191.1 | 265 | 85.5 |
≥ 191.1 | 45 | 14.5 |
FAR | ||
< 0.0726 | 176 | 56.8 |
≥ 0.0726 | 124 | 43.2 |
End-point | ||
Alive | 212 | 68.4 |
Dead | 98 | 31.6 |
Recurrence | ||
YES | 112 | 36.1 |
NO | 198 | 63.9 |
Metastasis | ||
YES | 61 | 19.7 |
NO | 249 | 80.3 |
Adjuvant therapy | ||
None | 257 | 82.9 |
Chemotherapy | 14 | 4.5 |
Radiotherapy | 16 | 5.2 |
Combined chemoradiotherapy | 2 | 0.6 |
Unknown | 21 | 6.8 |
Determination of the optimal cut-off value
Correlation between FAR and Clinicopathological characteristics
Variables | FAR | p-value | |
---|---|---|---|
< 0.0726, n (%) | ≥0.0726, n (%) | ||
Gender | |||
Male | 100 (56.8) | 74 (55.2) | 0.779 |
Female | 76 (43.2) | 60 (44.8) | |
Age (years) | |||
< 50 | 136 (77.3) | 72 (53.7) | <0.001 |
≥ 50 | 40 (22.7) | 62 (46.3) | |
Tumor size (cm) | <0.001 | ||
< 5 | 98 (55.7) | 45 (33.6) | |
≥ 5 | 78 (44.3) | 89 (66.4) | |
Tumor depth | <0.001 | ||
Superficial | 92 (52.3) | 35 (26.1) | |
Deep | 84 (47.7) | 99 (73.9) | |
Tumor grade | 0.002 | ||
G1 | 60 (34.1) | 22 (16.4) | |
G2 | 64 (36.4) | 55 (41.0) | |
G3 | 35 (19.9) | 45 (3.6) | |
Missing | 17 (9.7) | 12 (9.0) | |
AJCC stage | 0.001 | ||
IA + IB | 61 (34.7) | 22 (16.4) | |
IIA + IIB | 75 (42.6) | 66 (49.3) | |
III + IV | 25 (14.2) | 37 (27.6) | |
Unknown | 15 (8.5) | 9 (6.7) | |
NLR | |||
< 2.51 | 148 (84.1) | 66 (49.3) | <0.001 |
≥ 2.51 | 28 (15.9) | 68 (50.7) | |
PLR | <0.001 | ||
< 191.1 | 165 (93.8) | 100 (74.6) | |
≥ 191.1 | 11 (6.3) | 34 (25.4) | |
Recurrence | 0.001 | ||
YES | 50 (28.4) | 62 (46.3) | |
NO | 126 (71.6) | 72 (53.7) | |
Metastasis | 0.005 | ||
YES | 25 (14.2) | 36 (26.9) | |
NO | 151 (85.8) | 98 (73.1) |
Survival analysis
Variables | OS Univariate analysis | OS Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Sex | ||||
Male | 1 (referent) | |||
Female | 1.304 (0.877–1.937) | 0.190 | ||
Age (years) | ||||
< 50 | 1 (referent) | |||
≥ 50 | 1.195 (0.793–1.02) | 0.395 | ||
Tumor size (cm) | ||||
< 5 | 1 (referent) | |||
≥ 5 | 1.676 (1.109–2.535) | 0.014 | ||
Tumor depth | ||||
Superficial | 1 (referent) | 1 (referent) | ||
Deep | 3.174 (1.942–5.190) | <0.001 | 1.905 (1.098–3.305) | 0.022 |
Tumor grade | ||||
G1 | 1 (referent) | 1 (referent) | ||
G2 | 4.339 (1.821–10.336) | 0.001 | 3.090 (1.283–7.440) | 0.012 |
G3 | 10.918 (4.647–25.652) | <0.001 | 6.527 (2.715–15.693) | <0.001 |
AJCC stage | ||||
IA + IB | 1 (referent) | |||
IIA + IIB | 4.571 (2.065–10.115) | <0.001 | ||
III + IV | 9.540 (4.224–21.544) | <0.001 | ||
NLR | ||||
< 2.51 | 1 (referent) | |||
≥ 2.51 | 2.229 (1.497–3.318) | <0.001 | ||
PLR | ||||
< 191.1 | 1 (referent) | 1 (referent) | ||
≥ 191.1 | 3.585 (2.327–5.522) | <0.001 | 1.936 (1.175–3.188) | 0.009 |
FAR | ||||
< 0.0726 | 1 (referent) | 1 (referent) | ||
≥ 0.0726 | 3.147 (2.068–4.787) | <0.001 | 1.907 (1.161–3.132) | 0.011 |
Variables | DFS Univariate analysis | DFS Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Sex | ||||
Male | 1 (referent) | |||
Female | 1.014 (0.730–1.409) | 0.934 | ||
Age (years) | ||||
< 50 | 1 (referent) | 1 (referent) | ||
≥ 50 | 1.538 (1.103–2.145) | 0.011 | 1.601 (1.111–2.306) | 0.012 |
Tumor size (cm) | ||||
< 5 | 1 (referent) | |||
≥ 5 | 2.181 (1.537–3.093) | <0.001 | ||
Tumor depth | ||||
Superficial | 1 (referent) | 1 (referent) | ||
Deep | 3.006 (2.043–4.422) | <0.001 | 2.346 (1.541–3.571) | <0.001 |
Tumor grade | ||||
G1 | 1 (referent) | 1 (referent) | ||
G2 | 2.268 (1.340–3.837) | 0.002 | 1.798 (1.053–3.069) | 0.031 |
G3 | 5.300 (3.132–8.71) | <0.001 | 4.404 (2.565–7.561) | <0.001 |
AJCC stage | ||||
IA + IB | 1 (referent) | |||
IIA + IIB | 2.294 (1.402–3.751) | 0.001 | ||
III + IV | 5.089 (3.014–8.590) | <0.001 | ||
NLR | ||||
< 2.51 | 1 (referent) | 1 (referent) | ||
≥ 2.51 | 1.778 (1.271–2.487) | 0.001 | 1.719 (1.195–2.471) | 0.003 |
PLR | ||||
< 191.1 | 1 (referent) | |||
≥ 191.1 | 2.498 (1.688–3.698) | <0.001 | ||
FAR | ||||
< 0.0726 | 1 (referent) | |||
≥ 0.0726 | 1.956 (1.408–2.718) | <0.001 |